[
  {
    "ts": "2026-02-04T05:11:01+00:00",
    "headline": "How Investors Are Reacting To Incyte (INCY) EMA Boost For Zynyz In First-Line Anal Cancer",
    "summary": "In January 2026, Incyte announced that the EMA’s CHMP issued a positive opinion recommending approval of Zynyz (retifanlimab) plus platinum-based chemotherapy as first-line treatment for adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, based on Phase 3 data showing improved progression-free survival and no new safety signals. This marks a potential expansion of Incyte’s immuno-oncology footprint in Europe in a rare cancer where treatment...",
    "url": "https://finance.yahoo.com/news/investors-reacting-incyte-incy-ema-051101899.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "707fd637-2009-3958-b58f-835161d76500",
      "content": {
        "id": "707fd637-2009-3958-b58f-835161d76500",
        "contentType": "STORY",
        "title": "How Investors Are Reacting To Incyte (INCY) EMA Boost For Zynyz In First-Line Anal Cancer",
        "description": "",
        "summary": "In January 2026, Incyte announced that the EMA’s CHMP issued a positive opinion recommending approval of Zynyz (retifanlimab) plus platinum-based chemotherapy as first-line treatment for adults with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal, based on Phase 3 data showing improved progression-free survival and no new safety signals. This marks a potential expansion of Incyte’s immuno-oncology footprint in Europe in a rare cancer where treatment...",
        "pubDate": "2026-02-04T05:11:01Z",
        "displayTime": "2026-02-04T05:11:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-incyte-incy-ema-051101899.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-incyte-incy-ema-051101899.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T13:11:15+00:00",
    "headline": "TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen raised its price target for Incyte to $128 from $101 with a Buy rating on the shares. The firm’s optimism follows Incyte’s presentation of a strategic roadmap aimed at potentially tripling its revenue, excluding Jakafi, […]",
    "url": "https://finance.yahoo.com/news/td-cowen-keeps-buy-rating-131115743.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ba5edc66-8a8c-3481-a8ec-79be80b702bf",
      "content": {
        "id": "ba5edc66-8a8c-3481-a8ec-79be80b702bf",
        "contentType": "STORY",
        "title": "TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029",
        "description": "",
        "summary": "Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen raised its price target for Incyte to $128 from $101 with a Buy rating on the shares. The firm’s optimism follows Incyte’s presentation of a strategic roadmap aimed at potentially tripling its revenue, excluding Jakafi, […]",
        "pubDate": "2026-02-04T13:11:15Z",
        "displayTime": "2026-02-04T13:11:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/54064ea5aa5f17b3ea6086a8a9c9f45a",
          "originalWidth": 768,
          "originalHeight": 512,
          "caption": "TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BjGvGGE_p5O7cfXN1RxH0w--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/54064ea5aa5f17b3ea6086a8a9c9f45a.cf.webp",
              "width": 768,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gtg6gbfppIk2Ja9BFuYZMQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/54064ea5aa5f17b3ea6086a8a9c9f45a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/td-cowen-keeps-buy-rating-131115743.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/td-cowen-keeps-buy-rating-131115743.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-04T15:00:18+00:00",
    "headline": "Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?",
    "summary": "Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/royalty-pharma-rprx-earnings-expected-150018036.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "873b0c97-98b9-37ed-8ed0-daffbc32ec7a",
      "content": {
        "id": "873b0c97-98b9-37ed-8ed0-daffbc32ec7a",
        "contentType": "STORY",
        "title": "Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?",
        "description": "",
        "summary": "Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2026-02-04T15:00:18Z",
        "displayTime": "2026-02-04T15:00:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
          "originalWidth": 900,
          "originalHeight": 876,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7_MbG.UY.XzK7FHlqhSdQ--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 900,
              "height": 876,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9cdhr7KlQi2r1salrGcJQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/royalty-pharma-rprx-earnings-expected-150018036.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/royalty-pharma-rprx-earnings-expected-150018036.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RPRX"
            },
            {
              "symbol": "WSFX.BO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]